Clinical Trials Directory

Trials / Completed

CompletedNCT07316959

Efficacy of Long-Term Low Dose Macrolide Therapy in Preventing Early Recurrence of Nasal Polyps After Endoscopic Sinus Surgery

Efficacy Of Long-Term Low Dose Macrolide Therapy In Preventing Early Recurrence Of Nasal Polyps After Endoscopic Sinus Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Fatima Jinnah Medical University · Academic / Other
Sex
All
Age
15 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This randomized controlled trial evaluated the effectiveness of long-term, low-dose clarithromycin (250 mg/day) in reducing symptoms, improving endoscopic and radiologic scores, and preventing early recurrence of nasal polyps after endoscopic sinus surgery. Conducted at the ENT Department of Sir Ganga Ram Hospital, Lahore, the study included patients aged 15-75 undergoing surgery for nasal polyps. Group A received clarithromycin for three months in addition to standard therapy, while Group B received standard therapy alone. Patients treated with clarithromycin showed significantly greater improvements in SNOT, Lund-Kennedy, and Lund-Mackay scores at 8 and 12 weeks compared to controls (p\<0.05). Polyp recurrence at three months was also lower in the macrolide group (12%) than in the non-macrolide group (32%). Overall, low-dose clarithromycin was found to be safe and effective in enhancing postoperative outcomes and reducing early recurrence of nasal polyps after endoscopic sinus surgery.

Conditions

Interventions

TypeNameDescription
PROCEDUREclarithromycin 250 mgFollowing surgery, patients were split into two groups at random . For three months, patients in group A received Macrolide (clarithromycin 250 mg) once day in addition to their usual prescription drugs.

Timeline

Start date
2025-01-01
Primary completion
2025-06-01
Completion
2025-06-15
First posted
2026-01-05
Last updated
2026-01-06

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07316959. Inclusion in this directory is not an endorsement.